威廉希尔williamhill官方网站助力新加坡首个疫苗配液及灌装生产设施完工
2023年11月9日，新加坡卫生部长王乙康出席新加坡首个端到端外地疫苗开发机构ACES Manufacturing开业仪式并致辞，ACES Manufacturing由美国制药巨头默沙东与英国惠康信托基金配合拥有的合资企业Hilleman Laboratories在新加坡建设。
On November 9, 2023, Singapore's Minister for Health Ong Ye Kung attended and delivered a speech at the opening of ACES Manufacturing, Singapore’s first end-to-end local vaccine development facility in Singapore established by Hilleman Laboratories, which is an equal joint venture owned by the US pharmaceutical giant MSD and the Wellcome Trust of the United Kingdom.
威廉希尔williamhill官方网站科技集团有限公司很幸运加入该项目，并为新的ACES设施提供了MiniKUFill一体化灌装冻关连统、一次性系统和其他相关装备，配合资助加速了生产病毒疫苗的优异生产规范（GMP）设施的建设，特殊是针对埃博拉和拉沙热等低收入和中等收入国家（LMICs）疾病的疫苗。并因实时交货和现场高效装置而受到客户的高度评价。
Tofflon Science and Technology Group Co., Ltd. Was honored to participate in the project and provided the new ACES facility with the MiniKUFill integrated filling and lyophilization system, Single-Use Systems and other related equipment, which together helped accelerate the construction of the Good Manufacturing Practice (GMP) facility for the production of viral vaccines especially for diseases in low- and middle-income countries (LMICs) such as Ebola and Lassa Fever, and was highly lauded by the customer for timely delivery and efficient installation on site.
威廉希尔williamhill官方网站的MiniKUFill等装备使30,000平方米的研发和中试制造工厂实现了从上游质料药生产到下游制剂产品的高度无邪的� ？榛�。它可以顺应在统一条生产线上生产差别的疫苗平台。同时，该平台还将为新加坡外地生态系统以及中低收入国家的研发实体创立培训时机。
威廉希尔williamhill官方网站将一连深耕生物制药领域，起劲为海内外生物制药企业带来更好的装备和耗材，为行业的前进和生长孝顺力量。
Tofflon's MiniKUFill and other equipment have enabled the 30,000 square-meter R&D and pilot manufacturing plant to achieve highly flexible modular production from upstream drug substance production to downstream drug products. It can be adapted for the production of different vaccine platforms on the same production line. At the same time, the platform will also create training opportunities for the local Singapore ecosystem as well as R&D entities in LMICs.
Tofflon will continue to develop the field of biopharmaceuticals, strive to bring better equipment and consumables to biopharmaceutical companies at home and abroad, and contribute to the progress and development of the industry.
